- In patients with hyperuricaemia, febuxostat may slow the progression of chronic kidney disease (CKD), irrespective of baseline renal function without increasing the risk for major cardiovascular events, stroke, arrhythmias, joint pain and diarrhoea.
Why this matters
- Findings warrant future studies to better define the renoprotective effects and role of febuxostat in patients with hyperuricaemia.
- 9 randomised controlled trials (n=2141) met eligibility criteria after a search across electronic databases.
- Funding: None disclosed.
- Febuxostat vs placebo group had a higher estimated glomerular filtration rate (eGFR) at 6 months (weighted mean difference [WMD], 2.86 mL/min/1.73 m2; I2=96.6%) and end of study (WMD, 2.69 mL/min/1.73 m2; I2=98.0%; P<.001 for both>
- Febuxostat vs placebo group had lower:
- serum creatinine (WMD, −0.04 mg/dL; P<.001 and>
- systolic (WMD, −1.18 mmHg; P<.001 and diastolic mmhg p=".04;" i>2=65.9%) blood pressure.
- Heterogeneity among studies.